Fewer Than One in Four Weight Loss Patients Maintain GLP-1RA Therapy After Twelve Months

JAMA study shows under 25 percent of weight loss patients stay on GLP-1RAs for a year, with many switching between agents during active clinical management.

By: AXL Media

Published: Mar 10, 2026, 11:43 AM EDT

Source: The information in this article was sourced from JAMA Network Open

Declining Persistence Rates in Non Diabetic Weight Management

A comprehensive study published in JAMA Network Open has highlighted a significant challenge in the long-term management of obesity using glucagon-like peptide-1 receptor agonists (GLP-1RAs). Researchers tracking a large cohort of adults without diabetes found that fewer than 25 percent of patients remained on their prescribed medication after one year. This low rate of persistence raises critical questions about the sustainability of current pharmacological weight loss interventions and the factors that lead patients to abandon therapy despite the rising popularity of these agents.

Therapeutic Switching as a Sign of Active Management

While the high rate of discontinuation initially suggests a lack of treatment success, the study's authors point to a more nuanced reality involving medication switching. According to the research led by Luyu Xie, PharmD, PhD, many patients transitioned between different GLP-1RA agents during the 12 month period. This behavior often reflects proactive therapy adjustments by healthcare providers as they attempt to optimize results or navigate insurance coverage, rather than a total loss of interest or nonengagement from the patient side.

The Impact of Emerging Formulations on Patient Retention

The rapid evolution of the pharmaceutical landscape for weight management has introduced a variety of new formulations and agents into the market. As these new options become available, clinicians are increasingly likely to pivot their patients toward medications that may offer better tolerability or more significant weight loss milestones. This constant shifting of treatment plans contributes to the statistical appearance of low persistence, even as patients continue to seek medical intervention for their metabolic health.